
Lam Research Corporation (LRCX), a large-cap semiconductor firm, has received an 86% rating from Validea's "Patient Investor" model, which screens for predictable profitability, low debt, and reasonable valuations per Warren Buffett's strategy. This score indicates "some interest" in LRCX's fundamentals and valuation, positioning it as a potential candidate for long-term, value-oriented portfolios, notwithstanding a "Fail" on its Return on Total Capital criterion.
Lam Research Corporation (LRCX) has been rated favorably by Validea's Patient Investor model, which is based on Warren Buffett's investment principles, scoring 86 out of a possible 100. This score indicates a noteworthy alignment with criteria focused on long-term predictable profitability, low debt, and reasonable valuation, suggesting the large-cap semiconductor firm presents a compelling case for quality-focused investors. The company passed a majority of the model's fundamental tests, including key metrics such as earnings predictability, debt service capacity, return on equity, free cash flow generation, and shareholder-friendly use of retained earnings and share repurchases. However, the analysis also flagged a specific weakness, as LRCX failed the criterion for Return on Total Capital (ROTC), indicating that its efficiency in generating profits from its entire capital base may not meet the strategy's high standards. Despite this, the overall strong positive sentiment score of 0.85 for the ticker underscores the report's bullish tilt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment